[1]谭漪扬,周建中.慢性心力衰竭治疗新进展——LCZ696[J].心血管病学进展,2016,(1):42-45.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.011]
　TAN Yiyang,ZHOU Jianzhong.New Progression in Treatment of Chronic Heart Failure—LCZ696[J].Advances in Cardiovascular Diseases,2016,(1):42-45.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.011]
点击复制

慢性心力衰竭治疗新进展——LCZ696()
分享到：

《心血管病学进展》[ISSN:51-1187/R/CN:1004-3934]

卷:
期数:
2016年1期
页码:
42-45
栏目:
综述
出版日期:
2016-02-20

文章信息/Info

Title:
New Progression in Treatment of Chronic Heart Failure—LCZ696
作者:
谭漪扬; 周建中
重庆医科大学附属第一医院心内科,重庆 400016
Author(s):
TAN Yiyang; ZHOU Jianzhong
Department of Cardiology,The First Affiliated Hospital of Chongqing Medical University,Chongqing 400016,China
关键词:
LCZ696;  慢性心力衰竭;  血管紧张素受体-脑啡肽酶双重抑制
Keywords:
LCZ696;  Chronic heart failure;  Angiotensin receptor neprilysin inhibitor
分类号:
R541.6
DOI:
10.16806/j.cnki.issn.1004-3934.2016.01.011
文献标志码:
A
摘要:
心力衰竭即心脏的收缩功能和/或舒张功能发生障碍,不能将静脉回心血量充分排出心脏,导致肺循环和/或体循环淤血,从而引起心脏循环障碍症候群。在过去数十年中,都是以血管紧张素转换酶抑制剂/血管紧张素Ⅱ受体阻滞剂、β受体阻滞剂、醛固酮受体拮抗剂为主的药物进行治疗。而在最近,LCZ696作为一种新型血管紧张素受体-脑啡肽酶双重抑制类药物进入我们的视野,它同时具有抑制肾素-血管紧张素-醛固酮系统和脑啡肽酶的双重抑制作用从而治疗慢性心力衰竭。现就该药相关的药理作用、作用机制及临床效果做一综述。
Abstract:
When cardiac systolic and/or diastolic dysfunction, the venous return to the heart can not be fully discharge, which leads to pulmonary circulation and/or systemic circulation congestion and cause cardiac cycle dysfunction syndrome and possibly heart failure. Over the past few decades, the main drugs used to treat chronic heart failure were ACEI/ARB, beta blockers, and aldosterone antagonists. Recently a new type of drug, angiotensin receptor neprilysin inhibitor and named LCZ696 has been introduced. It has a dual inhibition of the renin angiotensin aldosterone system and enkephalinase. In this article, we reviewed the pharmacological action, mechanism and clinical effect of this new drug.

参考文献/References:

[1] Vardeny O, Tacheny T, Solomon SD. First-in-class angiotensin receptor neprilysin inhibitor in heart failure[J]. Clin Pharmacol Ther,2013,94(4):445-448.
[2] Trippodo NC, Fox M, Monticello TM, et al. Vasopeptidase inhibition with omapatrilat improves cardiac geometry and survival in cardiomyopathic hamsters more than does ACE inhibition with captopril[J]. J Cardiovasc Pharmacol,1999,34:782-790.
[3] Vardeny O, Miller R, Solomon SD. Combined neprilysin and renin-angiotensin system inhibition for the treatment of heart failure[J]. JACC Heart Fail,2014,2(6):663-670.
[4] Kostis JB, Packer M, Black HR,et al. Omapatrilat and enalapril in patients with hypertension:the Omapatrilat Cardiovascular Treatment vs. Enalapril(OCTAVE)trial[J]. Am J Hypertens,2004,17:103-111.
[5] Zucker IH, Xiao L, Haack KK,et al. The central renin-angiotensin system and sympathetic nerve activity in chronic heart failure[J].High Wire,2014,126(10):695-706.
[6] Komukai K, Yagi H, Ogawa T, et al. Inhibition of the renin-angiotensin system prevents re-hospitalization of heart failure patients with preserved ejection fraction[J]. Circ J,2008,72(12):2004-2008.
[7] Kapoun AM, Liang FQ, O'YoungG, et al. B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-β in primary human cardiac fibroblasts: fibrosis, myofibroblast conversion,proliferation, and inflammation[J]. Circ Res,2004,94(4):453-461.
[8] Cruden NL, Fox KA, Ludlam CA,et al. Neutral endopeptidase inhibition augments vascular actions of bradykinin in patients treated with angiotensin-converting enzyme inhibition[J]. Hypertension,2004,44:913-918.
[9] Daniels LB, Maisel AS. Natriuretic peptides[J]. J Am Coll Cardiol,2007,50(25):2357-2368.
[10] Martinez-Rumayor A, Richard AM, Burnett JC, et al. Biology of the natriuretic peptides[J]. Am J Cardiol,2008,101(suppl):3A-8A.
[11] Kostova E, Jovanoska E, Zafirov D, et al. Dual inhibition of angiotensin converting enzyme and neutral endopeptidase produces effective blood pressure control in spontaneously hypertensive rats[J].Bratisl Lek Listy,2005,106(12):407-411.
[12] Gu J, Noe A, Chandra P, et al. Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor(ARNi)[J]. J Clin Pharmacol,2010,50(4):401-414.
[13] Bhatia RS, Tu JV, Lee DS, et al. Outcome of heart failure with preserved ejection fraction in a population-based study[J]. N Engl J Med,2006,355:260-269.
[14] Aurigemma GP, Gaasch WH. Clinical practice. Diastolic heart failure[J]. N Engl J Med,2004,351:1097-1105.
[15] Solomon SD,Zile M,Pieske B,et al. The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction:a phase 2 double-blind randomised controlled trial[J]. Lancet,2012,380(9851):1387-1395.
[16] Green CP, Porter CB, Bresnahan DR, et al. Development and evaluation of the Kansas City Cardiomyopathy Questionnaire: a new health status measure for heart failure[J]. J Am Coll Cardiol,2000,35:1245-1255.
[17] Pardeep S,Brian C,Milton P,et al. Independence of the blood pressure lowering effect and efficacy of the angiotensin receptor neprilysin inhibitor, LCZ696, in patients with heart failure with preserved ejection fraction:an analysis of the PARAMOUNT trial[J].Eur J Heart Fail,2014,16:671-677.
[18] The CONSENSUS Trial Study Group.Effects of enalapril on mortality in severe congestive heart failure:results of the Cooperative North Scandinavian Enalapril Survival Study(CONSENSUS)[J]. N Engl J Med,1987,316:1429-1435.
[19] The SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure[J]. N Engl J Med,1991,325:293-302.
[20] McMurray JJ,Packer M,Desai AS,et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure[J]. N Engl J Med,2014,371(1):993-1004.
[21] Hillege HL, Girbes AR, de Kam PJ, et al.Renal function, neurohormonal activation, and surival in patients with chronic heart failure[J]. Circulation,2000,102:203-210.
[22] Seymour AA, Asaad MM, Lanoce VM, et al. Systemic hemodynamics, renal function and hormonal levels during inhibition of neutral endopeptidase 3.4.24.11 and angiotensin-converting enzyme in conscious dogs with pacing-induced heart failure[J]. J Pharmacol Exp Ther,1993,266:872-883.
[23] Ruilope LM, Dukat A, Böhm M, et al.Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensinⅡreceptor and neprilysin:a randomised, double-blind, placebo-controlled, active comparator study[J]. Lancet,2010,375:1255-1266.

备注/Memo

备注/Memo:
作者简介:谭漪扬(1990—),在读硕士,主要从事心衰药物治疗研究。Email: 514165335@qq.com
通信作者:周建中(1964—),主任医师,教授,硕士,主要从事心力衰竭、心律失常、高血压相关治疗研究。Email: 1115155663@qq.com
更新日期/Last Update: 2016-02-20